Details for Patent: 12,514,906
Which drugs does patent 12,514,906 protect, and when does it expire?
Patent 12,514,906 protects VOXZOGO and is included in one NDA.
This patent has forty-four patent family members in twenty-five countries.
Summary for Patent: 12,514,906
| Title: | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
| Abstract: | The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component. |
| Inventor(s): | Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap |
| Assignee: | Biomarin Pharmaceutical Inc |
| Application Number: | US18/425,954 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Device; |
Drugs Protected by US Patent 12,514,906
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-001 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES | ⤷ Start Trial | |||
| Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-002 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES | ⤷ Start Trial | |||
| Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-003 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,514,906
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 105563 | ⤷ Start Trial | |||
| Australia | 2016298425 | ⤷ Start Trial | |||
| Australia | 2023200669 | ⤷ Start Trial | |||
| Australia | 2026203845 | ⤷ Start Trial | |||
| Brazil | 112018001761 | ⤷ Start Trial | |||
| Canada | 2994280 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
